In vivo therapeutic success of MicroRNA-155 antagomir in a mouse model of pulmonary fibrosis induced by bleomycin
Open Access
- 1 March 2021
- journal article
- research article
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 36 (Suppl 1), S160-S169
- https://doi.org/10.3904/kjim.2019.098
Abstract
Background/Aims: MicroRNAs (miRNAs) play critical regulatory roles in the pathogenesis of pulmonary fibrosis. The aim of this study was to explore whether miRNA antagomirs could serve as potential therapeutic agents in interstitial lung diseases. Methods: A mouse model of pulmonary fibrosis was established by intratracheal injection of bleomycin (BLM). Using microarray analysis, up-regulated miRNAs were identified during the development of pulmonary fibrosis. miR-155 was chosen as the candidate miRNA. Fifteen mice were then randomized into the following three groups: BLM + antagomiR-155 group, treated with BLM plus intravenously injected with antagomiR-155; BLM group, treated with intratracheal BLM plus phosphate-buffered saline (PBS); and a control group, treated with PBS only. Lung tissues were collected for histopathological analysis, hydroxyproline measurement, and Western blotting. Enzyme-linked immunosorbent assays were used for the measurement of cytokines associated with pulmonary fibrosis. Results: Histological changes and hydroxyproline levels induced by BLM were significantly inhibited by antagomiR-155. The levels of interleukin 4 (IL-4) and transforming growth factor-beta (TGF-beta) expression were increased after BLM treatment. However, miR-155 silencing decreased the expression of IL-4, TGF-beta, and interferon-y. TGF-0-activated kinase i/mitogen-activated protein kinase kinase kinase 7 (MAP3K7)-binding protein 2 (TAB2) of the mitogen-activated protein kinase (MAPK) signaling pathway, was activated by BLM and inhibited by in vivo silencing of miR-155 via antagomiR-155. Conclusions: In vivo treatment with antagomiR-155 alleviated the pathological changes induced by BLM and may be a promising therapeutic strategy for pulmonary fibrosis.Keywords
Funding Information
- Shanghai Natural Science Foundation (16ZR1420600)
- Research Program of Shanghai College Teachers (101005.26.23)
This publication has 39 references indexed in Scilit:
- Antiflammin-1 attenuates bleomycin-induced pulmonary fibrosis in miceRespiratory Research, 2013
- A Micro RNA Processing Defect in Rapidly Progressing Idiopathic Pulmonary FibrosisPLOS ONE, 2011
- Comprehensive microRNA analysis in bleomycin-induced pulmonary fibrosis identifies multiple sites of molecular regulationPhysiological Genomics, 2011
- KEGG for representation and analysis of molecular networks involving diseases and drugsNucleic Acids Research, 2009
- Identification of Keratinocyte Growth Factor as a Target of microRNA-155 in Lung Fibroblasts: Implication in Epithelial-Mesenchymal InteractionsPLOS ONE, 2009
- TGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTENNature, 2009
- The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?The International Journal of Biochemistry & Cell Biology, 2008
- Common and unique mechanisms regulate fibrosis in various fibroproliferative diseasesJCI Insight, 2007
- RNAi: The Nuts and Bolts of the RISC MachineCell, 2005
- IL-4 Upregulates Tenascin Synthesis in Scleroderma and Healthy Skin FibroblastsJournal of Investigative Dermatology, 1996